Defining signaling pathways and effective combination therapy to improve outcomes for patients with FGFR2-driven biliary cancer

Ended Project Grant Awarded Last action

Award ID
W81XWH2210345
Recipient
Awarding agency
Obligated
$936,000

Award facts

Assistance listing
12.420 Military Medical Research and Development
Completion date
Place of performance
Cambridge, MA 02142, USA

Award details come from USAspending.gov.

About this award

Written by GovTribe AI ·

The Broad Institute, Inc. was awarded a $936,000 Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development federal grant program (CFDA 12.420). The four-year award will fund research to define signaling pathways and effective combination therapies to improve outcomes for patients with FGFR2-driven biliary cancer. Through support of basic, applied, and advanced biomedical research, the Military Medical Research and Development program aims to transform health care for service members and the public by investigating medical solutions for the battlefield and beyond. This award will support The Broad Institute's work developing precision medicine approaches with the goal of improving prognosis for those suffering from this rare but deadly form of cancer.

Quick answers

Who received award W81XWH2210345?

W81XWH2210345 was awarded to The Broad Institute, Inc. by Medical Command (Department of the Army) on May 15, 2022.

How much is award W81XWH2210345 worth?

$936,000 has been obligated on W81XWH2210345.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login